Aquestive Therapeutics, Inc. (AQST) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -78.23M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-78.23M | (m) |
| 2026-03-31 | (m) | $-68.91M | (m) |
| 2025-12-31 | (m) | $-83.78M | (m) |
| 2025-09-30 | (m) | $-68.98M | (m) |
| 2025-06-30 | (m) | $-65.04M | (m) |
| 2025-03-31 | (m) | $-54.24M | (m) |
| 2024-12-31 | (m) | $-44.14M | (m) |
| 2024-09-30 | (m) | $-35.19M | (m) |
| 2024-06-30 | (m) | $-25.72M | (m) |
| 2024-03-31 | (m) | $-28.77M | (m) |
| 2023-12-31 | (m) | $-7.87M | (m) |
| 2023-09-30 | (m) | $-12.11M | (m) |
| 2023-06-30 | (m) | $-22.61M | (m) |
| 2023-03-31 | (m) | $-33.12M | (m) |
| 2022-12-31 | (m) | $-54.41M | (m) |
| 2022-09-30 | (m) | $-71.00M | (m) |
| 2022-06-30 | (m) | $-73.02M | (m) |
| 2022-03-31 | (m) | $-69.09M | (m) |
| 2021-12-31 | (m) | $-70.54M | (m) |
| 2021-09-30 | (m) | $-61.96M | (m) |
| 2021-06-30 | (m) | $-63.96M | (m) |
| 2021-03-31 | (m) | $-53.92M | (m) |
| 2020-12-31 | (m) | $-55.78M | (m) |
| 2020-09-30 | (m) | $-48.05M | (m) |
| 2020-06-30 | (m) | $-49.91M | (m) |
| 2020-03-31 | (m) | $-68.05M | (m) |
| 2019-12-31 | (m) | $-66.25M | (m) |
| 2019-09-30 | (m) | $-67.55M | (m) |
| 2019-06-30 | (m) | $-64.18M | (m) |
| 2019-03-31 | (m) | $-80.20M | (m) |
| 2018-12-31 | (m) | $-61.38M | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
| 2018-03-31 | (m) | $-3.39M | (m) |
| 2017-12-31 | (m) | $-8.94M | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |